Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC
Monkeypox
About this trial
This is an interventional prevention trial for Monkeypox
Eligibility Criteria
Inclusion Criteria: Provides written informed consent 18 years of age or older At high risk for Monkeypox infections Personnel and staff associated with the PALM 007-Monkeypox study sites in the DRC Willingness and ability to communicate AEs to study personnel Exclusion Criteria: Allergy to MVA-BN or any of its components Pregnant or breastfeeding women Fever (axillary temperature ≥37.5°celsius) People who have already received the MVA-BN vaccine (in routine vaccination or another study involving this vaccine) Participants who, in the judgement of the investigator, will be at significantly increased risk as a result of participation in the study Individuals with any condition or circumstance that would render them unable to comply with study procedures (e.g., not reachable by phone)
Sites / Locations
- Institut National de Rescherche Biomédicale (INRB)
- L'Hôpital Général de Référence de KoleRecruiting
- L'Hôpital Général de Référence de Tunda
Arms of the Study
Arm 1
Experimental
MVA-BN vaccine
2 doses of 0.5 mL MVA-BN vaccine injected subcutaneously and given at least 28 days apart